More news on Isturisa for Cushing’s

In a recent press release, Recordati Rare Diseases Inc., a biopharmaceutical company committed to developing therapies for rare disease communities of the United States, announced the full availability of Isturisa® for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative. Isturisa® mechanistically inhibits the final step of the cortisol synthesis pathway. Achieving control of cortisol production is an important strategy to help patients manage Cushing’s disease, and it may be crucial for mitigating the risk for comorbidities associated with hypercortisolism.  Click here to read the complete Press Release

Isturisa®® will be available exclusively through the R.A.R.E.™ (Recordati, Access, Resources, and Engagement) Patient Support Program, an initiative created by Recordati in partnership with AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions. In addition to prescription fulfillment, the R.A.R.E Patient Support Program will provide insurance benefits investigation, educational support, resources for qualified patients to obtain financial assistance, and other services designed to help patients access treatment.

Read the press release here

© 2020, Pituitary World News. All rights reserved.

LEAVE A REPLY

Please enter your comment!
Please enter your name here